Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Sarah Abou AlaiwiWanling XieAmin H NassarShaan DudaniDylan MartiniZiad BakounyJohn A SteinharterPier Vitale NuzzoRonan FlippotNieves Martinez-ChanzaXiao WeiBradley A McGregorMarina D KaymakcalanDaniel Y C HengMehmet A BilenToni K ChoueiriLauren C HarshmanPublished in: Journal for immunotherapy of cancer (2020)
Despite a considerable rate of irAE recurrence with retreatment after a prior clinically significant irAE, most irAEs were low grade and controllable. Prospective studies are warranted to confirm that retreatment enhances survival outcomes that justify the safety risks.